Study of Performance of Confocal Endomicroscope With Fluorescein Imaging Agent in the Colon
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- University of Michigan
- Enrollment
- 72
- Locations
- 1
- Primary Endpoint
- Depth-imaging capability of the confocal endomicroscope using an imaging contrast agent, fluorescein
Study Overview
Brief Summary
The overall aim of this research project is to evaluate the imaging performance of a confocal endomicroscope. Fluorescein, an FDA-approved topical fluorescent dye, will be used to provide topical mucosal contrast. The purpose of this instrument is to provide real-time endoscopic "histology" to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group. This endomicroscope probe will be used during colonoscopies in subjects with colonic dysplasia, known colonic adenomatous polyps scheduled for endoscopic resection, or suspected dysplasia in subjects with Inflammatory Bowel Disease (IBD).
Detailed Description
The device is being tested in small groups of individuals: generally less than 10 for each of a variety of histologically different colonic lesions or diseases (eg. IBD, adenomas, sessile seriated adenomas (SSAs), hyperplastic polyps, normal tissue).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Device Feasibility
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 100 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject meets at least one of the following criteria:
- •At increased risk for colorectal cancer and colonic polyps
- •Known colonic adenomas scheduled for colonic polyp resection
- •Scheduled for outpatient colonoscopy for follow up surveillance of IBD with known dysplasia or who are at high risk for high grade dysplasia.
Exclusion Criteria
- •Subject meets all of the following criteria:
- •Subject is scheduled for outpatient colonoscopy in the Medical Procedures Unit at University of Michigan Health System.
- •Subject is medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities) Standard practice guidelines for safely proceeding with the procedure will be sufficient for our study.
- •Age 18 to 100 years
- •Willing and able to sign informed consent
Arms & Interventions
Subjects with abnormal colon tissue
The study subjects will be high-risk for colonic adenomas (i.e. strong family history of adenomas/adenocarcinoma or personal history of adenomas/adenocarcinoma), known adenoma scheduled for endoscopic resection, or in subjects with suspected dysplasia in inflammatory bowel disease (IBD). Fluorescein will be sprayed on the area of interest to provide imaging contrast for the images taken with the confocal endomicroscope.
Intervention: confocal endomicroscope (Device)
Subjects with abnormal colon tissue
The study subjects will be high-risk for colonic adenomas (i.e. strong family history of adenomas/adenocarcinoma or personal history of adenomas/adenocarcinoma), known adenoma scheduled for endoscopic resection, or in subjects with suspected dysplasia in inflammatory bowel disease (IBD). Fluorescein will be sprayed on the area of interest to provide imaging contrast for the images taken with the confocal endomicroscope.
Intervention: Fluorescein (Drug)
Outcomes
Primary Outcomes
Depth-imaging capability of the confocal endomicroscope using an imaging contrast agent, fluorescein
Time Frame: five minutes
The test product efficacy will be assessed by evaluating the fluorescence intensities measured from suspicious regions of colonic mucosa where the agent is administered compared to adjacent normal mucosa.
Secondary Outcomes
No secondary outcomes reported
Investigators
Danielle Kim Turgeon
Professor of Internal Medicine and Clinical Track Faculty Ombuds, Medical School
University of Michigan